Cost-effectiveness of additional blood screening tests in the Netherlands

Transfusion

Volumn 52, Issue 3, 2012, Pages 478-488

  Borkent Raven, Barbara A ^a,b,c   Janssen, Mart P ^a,b,c   Van Der Poel, Cees L ^a,b,c   Bonsel, Gouke J ^a,b,c   Van Hout, Ben A ^a,b,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD EXAMINATION; COST EFFECTIVENESS ANALYSIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; NETHERLANDS; NUCLEIC ACID AMPLIFICATION; QUALITY ADJUSTED LIFE YEAR;

ADOLESCENT; ADULT; AGED; BLOOD BANKS; BLOOD DONORS; COST-BENEFIT ANALYSIS; DELTARETROVIRUS INFECTIONS; HEPATITIS C; HIV INFECTIONS; HTLV-I INFECTIONS; HUMANS; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PREVALENCE; QUESTIONNAIRES; VIRUS DISEASES; YOUNG ADULT;

EID: 84858226214     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03319.x     Document Type: Article

References (37)

1. Alter HJ, Klein HG,. The hazards of blood transfusion in historical perspective. Blood 2008; 112: 2617-26.
2. van Hulst M, de Wolf JT, Staginnus U, Ruitenberg EJ, Postma MJ,. Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang 2002; 83: 146-55. (Pubitemid 36807289)
3. McCabe C, Claxton K, Culyer AJ,. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 2008; 26: 733-44.
4. Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood componentsand amending Directive 2001/83/EC. 2003 Feb 8.
5. Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ, van Hout BA,. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion 2006; 46: 956-65. (Pubitemid 43800914)
6. van Hulst M, Bilgin YM, van de Watering LM, de Vries R, van Oers MH, Brand A, Postma MJ,. Cost-effectiveness of leucocyte-depleted erythrocyte transfusion in cardiac valve surgery. Transfus Med 2005; 15: 209-17. (Pubitemid 40827474)
7. Borkent-Raven BA, Janssen MP, van der Poel CL, Schaasberg WP, Bonsel GJ, van Hout BA,. The PROTON study: profiles of blood product transfusion recipients in the Netherlands. Vox Sang 2010; 99: 54-64.
8. Kleinman S,. Residual risk of transfusion transmitted viral infections among seronegative donors: application of the incidence/window period model. Dev Biol Stand 2000; 102: 61-5.
9. Sanquin annual reports. Amsterdam: Sanquin Blood Supply Foundation; 2011.
10. Stigum H, Magnus P, Samdal HH, Nord E,. Human T-cell lymphotropic virus testing of blood donors in Norway: a cost-effect model. Int J Epidemiol 2000; 29: 1076-84. (Pubitemid 32040806)
11. Pennington J, Taylor GP, Sutherland J, Davis RE, Seghatchian J, Allain JP, Williamson LM,. Persistence of HTLV-I in blood components after leukocyte depletion. Blood 2002; 100: 677-81. (Pubitemid 34761135)
12. Termorshuizen F, Dorigo-Zetsma JW, de Melker HE, van den Hof S, Conyn-Van Spaendonck MA,. The prevalence of antibodies to hepatitis A virus and its determinants in The Netherlands: a population-based survey. Epidemiol Infect 2000; 124: 459-66. (Pubitemid 30623863)
13. Borkent-Raven BA, Janssen MP, van der Poel CL, de Wit GA, Bonsel GJ, van Hout BA,. Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands. Transfusion 2009; 49: 311-9.
14. Pereira A, Sanz C,. A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols. Transfusion 2000; 40: 1182-91.
15. Helsper CW, Borkent-Raven BA, de Wit NJ, van Essen GA, Bonten MJ, Janssen MP, Hoepelman AI, de Wit GA,. Cost-effectiveness of targeted screening for hepatitis C in the Netherlands. Epidemiol Infect 2011; 16: 1-12.
16. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB,. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425-32. (Pubitemid 36250066)
17. van Hulst M, Hubben GA, Sagoe KW, Promwong C, Permpikul P, Fongsatitkul L, Glynn DM, Sibinga CT, Postma MJ,. Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands. Transfusion 2009; 49: 2729-42.
18. Stover J,. AIM: a computer program for making HIV/AIDS projections and examining the demographic and social impacts of AIDS. Washington (DC): Futures Group International, Health Policy Initiative, Task Order 1; 2009.
19. Jacobs RJ, Greenberg DP, Koff RS, Saab S, Meyerhoff AS,. Regional variation in the cost effectiveness of childhood hepatitis A immunization. Pediatr Infect Dis J 2003; 22: 904-14. (Pubitemid 37288614)
20. Borkent-Raven BA, Janssen MP, van der Poel CL, Schaasberg WP, Bonsel GJ, van Hout BA,. Survival after transfusion in the Netherlands. Transfusion 2010; 100: 196-203.
21. Sterftequotiënten naar leeftijd op laatste verjaardag en geslacht 1995/1996-1999/2000 (Data File). Statline electronic database of Statistics Netherlands. Statistics Netherlands; 2002.
22. Oppe M, Rabin R, Weijnen T, de Charro F, Rebolj M,. Modeling age dependency of self-reported health states and EQ vas ratings for different countries. In Discussion papers 20th plenary meeting of the EuroQol group. Ministry of Health: Republic of Slovenia; 2004.
23. Rodenburg-van Dieten HE,. Richtlijnen voor farmaco-economisch onderzoek; evaluatie en actualisatie. 2005 Oct 27. Report No.: RIVM rapport 24088606.
24. Weusten JJ, van Drimmelen HA, Lelie PN,. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 2002; 42: 537-48.
25. Busch MP, Kleinman SH, Jackson B, Stramer SL, Hewlett I, Preston S,. Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion 2000; 40: 143-59.
26. Bevolking op 1 januari; leeftijd, geslacht, burgerlijke staat (data file). Statline electronic database of Statistics Netherlands. Statistics Netherlands; 2009.
27. Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dodd RY,. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49 Suppl 2: 1S-29S.
28. Vamvakas EC, Taswell HF,. Long-term survival after blood transfusion. Transfusion 1994; 34: 471-7. (Pubitemid 24209656)
29. Tynell E, Andersson S, Lithander E, Arneborn M, Blomberg J, Hansson HB, Krook A, Nomberg M, Ramstedt K, Shanwell A, Bjorkman A,. Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis. BMJ 1998; 316: 1417-22. (Pubitemid 28211988)
30. Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, Weinstein MC,. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004; 86: 28-40. (Pubitemid 38200453)
31. Kleinman SH, Lelie N, Busch MP,. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009; 49: 2454-89.
32. Sculpher M,. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics 2008; 26: 799-806.
33. AuBuchon JP, Birkmeyer JD, Busch MP,. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion 1997; 37: 45-51. (Pubitemid 27068939)
34. Pereira A,. Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union. Transfusion 2003; 43: 192-201. (Pubitemid 36207299)
35. Busch MP, Dodd RY, Lackritz EM, AuBuchon JP, Birkmeyer JD, Petersen LR,. Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections. The HIV Blood Donor Study Group. Transfusion 1997; 37: 1003-11. (Pubitemid 27459584)
36. Loubiere S, Rotily M, Durand-Zaleski I, Costagliola D,. Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective. Vox Sang 2001; 80: 199-204. (Pubitemid 35334309)
37. Jackson BR, Busch MP, Stramer SL, AuBuchon JP,. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43: 721-9. (Pubitemid 36629116)